Cargando…

Polycaprolactone/maltodextrin nanocarrier for intracellular drug delivery: formulation, uptake mechanism, internalization kinetics, and subcellular localization

Prostate cancer (PCa) disease progression is associated with significant changes in intracellular and extracellular proteins, intracellular signaling mechanism, and cancer cell phenotype. These changes may have direct impact on the cellular interactions with nanocarriers; hence, there is the need fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Korang-Yeboah, Maxwell, Gorantla, Yamini, Paulos, Simon A, Sharma, Pankaj, Chaudhary, Jaideep, Palaniappan, Ravi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4524459/
https://www.ncbi.nlm.nih.gov/pubmed/26251597
http://dx.doi.org/10.2147/IJN.S75101
_version_ 1782384199849738240
author Korang-Yeboah, Maxwell
Gorantla, Yamini
Paulos, Simon A
Sharma, Pankaj
Chaudhary, Jaideep
Palaniappan, Ravi
author_facet Korang-Yeboah, Maxwell
Gorantla, Yamini
Paulos, Simon A
Sharma, Pankaj
Chaudhary, Jaideep
Palaniappan, Ravi
author_sort Korang-Yeboah, Maxwell
collection PubMed
description Prostate cancer (PCa) disease progression is associated with significant changes in intracellular and extracellular proteins, intracellular signaling mechanism, and cancer cell phenotype. These changes may have direct impact on the cellular interactions with nanocarriers; hence, there is the need for a much-detailed understanding, as nanocarrier cellular internalization and intracellular sorting mechanism correlate directly with bioavailability and clinical efficacy. In this study, we report the differences in the rate and mechanism of cellular internalization of a biocompatible polycaprolactone (PCL)/maltodextrin (MD) nanocarrier system for intracellular drug delivery in LNCaP, PC3, and DU145 PCa cell lines. PCL/MD nanocarriers were designed and characterized. PCL/MD nanocarriers significantly increased the intracellular concentration of coumarin-6 and fluorescein isothiocyanate-labeled bovine serum albumin, a model hydrophobic and large molecule, respectively. Fluorescence microscopy and flow cytometry analysis revealed rapid internalization of the nanocarrier. The extent of nanocarrier cellular internalization correlated directly with cell line aggressiveness. PCL/MD internalization was highest in PC3 followed by DU145 and LNCaP, respectively. Uptake in all PCa cell lines was metabolically dependent. Extraction of endogenous cholesterol by methyl-β-cyclodextrin reduced uptake by 75%±4.53% in PC3, 64%±6.01% in LNCaP, and 50%±4.50% in DU145, indicating the involvement of endogenous cholesterol in cellular internalization. Internalization of the nanocarrier in LNCaP was mediated mainly by macropinocytosis and clathrin-independent pathways, while internalization in PC3 and DU145 involved clathrin-mediated endocytosis, clathrin-independent pathways, and macropinocytosis. Fluorescence microscopy showed a very diffused and non-compartmentalized subcellular localization of the PCL/MD nanocarriers with possible intranuclear localization and minor colocalization in the lysosomes with time.
format Online
Article
Text
id pubmed-4524459
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-45244592015-08-06 Polycaprolactone/maltodextrin nanocarrier for intracellular drug delivery: formulation, uptake mechanism, internalization kinetics, and subcellular localization Korang-Yeboah, Maxwell Gorantla, Yamini Paulos, Simon A Sharma, Pankaj Chaudhary, Jaideep Palaniappan, Ravi Int J Nanomedicine Original Research Prostate cancer (PCa) disease progression is associated with significant changes in intracellular and extracellular proteins, intracellular signaling mechanism, and cancer cell phenotype. These changes may have direct impact on the cellular interactions with nanocarriers; hence, there is the need for a much-detailed understanding, as nanocarrier cellular internalization and intracellular sorting mechanism correlate directly with bioavailability and clinical efficacy. In this study, we report the differences in the rate and mechanism of cellular internalization of a biocompatible polycaprolactone (PCL)/maltodextrin (MD) nanocarrier system for intracellular drug delivery in LNCaP, PC3, and DU145 PCa cell lines. PCL/MD nanocarriers were designed and characterized. PCL/MD nanocarriers significantly increased the intracellular concentration of coumarin-6 and fluorescein isothiocyanate-labeled bovine serum albumin, a model hydrophobic and large molecule, respectively. Fluorescence microscopy and flow cytometry analysis revealed rapid internalization of the nanocarrier. The extent of nanocarrier cellular internalization correlated directly with cell line aggressiveness. PCL/MD internalization was highest in PC3 followed by DU145 and LNCaP, respectively. Uptake in all PCa cell lines was metabolically dependent. Extraction of endogenous cholesterol by methyl-β-cyclodextrin reduced uptake by 75%±4.53% in PC3, 64%±6.01% in LNCaP, and 50%±4.50% in DU145, indicating the involvement of endogenous cholesterol in cellular internalization. Internalization of the nanocarrier in LNCaP was mediated mainly by macropinocytosis and clathrin-independent pathways, while internalization in PC3 and DU145 involved clathrin-mediated endocytosis, clathrin-independent pathways, and macropinocytosis. Fluorescence microscopy showed a very diffused and non-compartmentalized subcellular localization of the PCL/MD nanocarriers with possible intranuclear localization and minor colocalization in the lysosomes with time. Dove Medical Press 2015-07-29 /pmc/articles/PMC4524459/ /pubmed/26251597 http://dx.doi.org/10.2147/IJN.S75101 Text en © 2015 Korang-Yeboah et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Korang-Yeboah, Maxwell
Gorantla, Yamini
Paulos, Simon A
Sharma, Pankaj
Chaudhary, Jaideep
Palaniappan, Ravi
Polycaprolactone/maltodextrin nanocarrier for intracellular drug delivery: formulation, uptake mechanism, internalization kinetics, and subcellular localization
title Polycaprolactone/maltodextrin nanocarrier for intracellular drug delivery: formulation, uptake mechanism, internalization kinetics, and subcellular localization
title_full Polycaprolactone/maltodextrin nanocarrier for intracellular drug delivery: formulation, uptake mechanism, internalization kinetics, and subcellular localization
title_fullStr Polycaprolactone/maltodextrin nanocarrier for intracellular drug delivery: formulation, uptake mechanism, internalization kinetics, and subcellular localization
title_full_unstemmed Polycaprolactone/maltodextrin nanocarrier for intracellular drug delivery: formulation, uptake mechanism, internalization kinetics, and subcellular localization
title_short Polycaprolactone/maltodextrin nanocarrier for intracellular drug delivery: formulation, uptake mechanism, internalization kinetics, and subcellular localization
title_sort polycaprolactone/maltodextrin nanocarrier for intracellular drug delivery: formulation, uptake mechanism, internalization kinetics, and subcellular localization
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4524459/
https://www.ncbi.nlm.nih.gov/pubmed/26251597
http://dx.doi.org/10.2147/IJN.S75101
work_keys_str_mv AT korangyeboahmaxwell polycaprolactonemaltodextrinnanocarrierforintracellulardrugdeliveryformulationuptakemechanisminternalizationkineticsandsubcellularlocalization
AT gorantlayamini polycaprolactonemaltodextrinnanocarrierforintracellulardrugdeliveryformulationuptakemechanisminternalizationkineticsandsubcellularlocalization
AT paulossimona polycaprolactonemaltodextrinnanocarrierforintracellulardrugdeliveryformulationuptakemechanisminternalizationkineticsandsubcellularlocalization
AT sharmapankaj polycaprolactonemaltodextrinnanocarrierforintracellulardrugdeliveryformulationuptakemechanisminternalizationkineticsandsubcellularlocalization
AT chaudharyjaideep polycaprolactonemaltodextrinnanocarrierforintracellulardrugdeliveryformulationuptakemechanisminternalizationkineticsandsubcellularlocalization
AT palaniappanravi polycaprolactonemaltodextrinnanocarrierforintracellulardrugdeliveryformulationuptakemechanisminternalizationkineticsandsubcellularlocalization